Advertisement
Advertisement
U.S. Markets close in 55 mins
Advertisement
Advertisement
Advertisement
Advertisement

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.04+0.30 (+2.79%)
As of 03:05PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.74
Open10.66
Bid11.00 x 800
Ask11.01 x 1000
Day's Range10.69 - 11.08
52 Week Range8.60 - 25.39
Volume737,467
Avg. Volume2,495,656
Market Cap2.937B
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-0.97
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.90
  • GlobeNewswire

    Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference

    PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therap

  • GlobeNewswire

    Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

    PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021. Digital Poster Presentations: Long-term multisystemic efficacy with migalastat in ERT-naïve and ERT-experienced patients with amenable GLA variants Presenter: Drago Bratkovic, MD, PARC Research Clinic, Adelaide, Australi

  • GlobeNewswire

    The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

    Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed to Provide a Differentiated Mechanism of Action and Potential Alternative Treatment Option for People Living with Late-onset Pompe Disease PHILADELPHIA, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and comm

Advertisement
Advertisement